Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 15/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21378470 | 0.84 | ACACB (0.52) | ACACBPOLBRAB9AALDH1A1HTT | |
| SCHEMBL21378468 | 0.84 | ACACB (0.52) | ACACBPOLBRAB9AALDH1A1HTT | |
| SCHEMBL21378570 | 0.81 | HRH3 (0.51) | ACACBPOLBRAB9AALDH1A1 | |
| SCHEMBL21378567 | 0.81 | HRH3 (0.51) | ACACBPOLBRAB9AALDH1A1 | |
| SCHEMBL18459334 | 0.77 | RAB9A (0.47) | ACACBPOLBRAB9AALDH1A1HTT | |
| SCHEMBL18459333 | 0.77 | RAB9A (0.47) | ACACBPOLBRAB9AALDH1A1HTT | |
| SCHEMBL20101837 | 0.76 | ALDH1A1 (0.43) | POLBALDH1A1HTTSMN1; SMN2FAAH | |
| SCHEMBL20270868 | 0.71 | HTT (0.49) | ACACBALDH1A1HTT | |
| SCHEMBL19700902 | 0.71 | HTT (0.49) | ACACBALDH1A1HTT | |
| SCHEMBL16546197 | 0.69 | ALDH1A1 (0.51) | POLBALDH1A1HTTFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118759-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIR USE AS MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118759-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIR USE AS MUTANT IDH1 INHIBITORS | IDH1, IDH3A, IDH3B | ACACB 1953/4885POLB 242/4885RAB9A 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.